BridgeBio Pharma Inc and Eidos Therapeutics Inc Announce Merger Agreement - Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the BridgeBio Pharma conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Dr. Neil Kumar, Founder and CEO. Please go ahead, sir.
Thank you so much, and thanks, everyone, for taking the time, especially amidst a very busy morning for biotech and biology news. As is typical, we'll be making forward-looking statements today, and you can read through the details of those in the first 2 pages.
I'll be referring to the announcement deck throughout, and we'll call out page numbers so that you can follow along. This call is set up to address the transaction highlighted on Page 4 of that document. BridgeBio will be acquiring all outstanding shares of Eidos Therapeutics for a 41% premium to the unaffected Eidos closing price this past Friday. The details of the deal are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |